Results 211 to 220 of about 20,922 (255)
Some of the next articles are maybe not open access.

A photoactivated prodrug

Bioorganic & Medicinal Chemistry Letters, 1998
A photolabile derivative (1) of the anticancer drug, 5-fluorodeoxyuridine (2), was designed and synthesized as a model prodrug. Photolysis of 1 with long-wavelength UV light rapidly released 2 in solution. While compound 1 alone is nontoxic to cells, the presence of both 1 and UV irradiation (lambda = 350 nm) resulted in potent inhibition of cell ...
Y, Wei, Y, Yan, D, Pei, B, Gong
openaire   +2 more sources

Polymeric prodrugs

International Journal of Pharmaceutics, 2004
In 1975 Prof. H. Ringsdorf proposed a model for rational design of polymeric prodrugs [J. Polym. Sci. Symp. 51 (1975) 135]. The model has been the most important basis for research in the field, since it was the first model that took into account both the chemical and biological aspects needed for the design of polymeric prodrugs. This paper deals with
K, Hoste, K, De Winne, E, Schacht
openaire   +2 more sources

Leucovorin as a Prodrug

1993
To exert its antitumor effects, leucovorin must ultimately become activated by conversion to CH2FH4.* Elevation of this reduced folate cofactor stabilizes the inhibitory ternary complex formed between the FU active metabolite, FdUMP and thymidylate synthase, resulting in suppression of DNA synthesis or repair.1–4 It has been demonstrated both in animal
D G, Priest, J C, Schmitz, T, Walle
openaire   +2 more sources

Bisphosphonate Prodrugs

Current Medicinal Chemistry, 2002
Bisphosphonates (BP) are pyrophosphate analogs having a P-C-P backbone. The oral bioavailability of BPs is ca. 1%, due to high ionisation at physiological pH. Using the prodrug approach, oral absorption can be increased by masking one or more ionizable groups (clodronate, etidronate), or using a targeting carrier system (alendronate, pamitronate).
openaire   +2 more sources

Heterocyclic NO prodrugs

Il Farmaco, 1999
An overview of the different heterocyclic NO-releasing compounds is given. Mesoionic heterocycles like sydnone imines are one example. This class is discussed on the synthesis and the mechanism of NO formation from Molsidomine and its first metabolite SIN-1.
openaire   +2 more sources

Prodrugs in Cancer Chemotherapy

Xenobiotica, 1986
At present, chemotherapy is not very effective against common solid cancers especially once they have metastasised. However, laboratory experiments and studies on dose intensification in humans have indicated that some anti-cancer agents might be curative but only if the dose given was very much higher than that presently obtainable clinically ...
openaire   +2 more sources

PRODRUG

2023
A Prodrug is a specialized substance designed to contain the parent drug while remaining either inactive or only partially active. These molecules are intentionally engineered to undergo biotransformation within the body, either through chemical or enzymatic cleavage, in order to release the active compound at levels suitable for therapeutic effects ...
openaire   +1 more source

Activation of Prodrugs Depend on the Metabolism of These Prodrugs

Current Research in Medical Sciences
Prodrugs depend on enzymatic processes, essentially in the liver, but can also occur in other tissues to release the active metabolite. These metabolic biotransformations are often enzymatically controlled, ensuring the drug becomes pharmacologically active at its site of action.
Rezk R. Ayyad   +5 more
openaire   +1 more source

Enamine Prodrugs

Journal of Pharmaceutical Sciences, 1971
H C, Caldwell   +6 more
openaire   +2 more sources

Prodrugs

2021
Zeynep Ates-Alagoz, Adeboye Adejare
openaire   +2 more sources

Home - About - Disclaimer - Privacy